Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma-Reference-Cited by-同舟云学术

Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma

Published:2023-11 Issue:5 Volume:131 Page:668-670
ISSN:1081-1206
Container-title:Annals of Allergy, Asthma & Immunology
language:en
Short-container-title:Annals of Allergy, Asthma & Immunology

Author:

Hernandez Camellia L.,Lynch Donna‐Marie,Golash Abby Jane,Marquis Kathleen,Besz Kylie Marie,Oxnard Geoffrey,Rotow Julia,DeAngelo Daniel J.,Castells Mariana

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Immunology

Reference10 articles.

1. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

2. Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation;Makimoto;Intern Med,2020

3. Use of omalizumab to achieve successful desensitization after oxaliplatin anaphylaxis;Cahill;J Allergy Clin Immunol,2012

4. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology;Giannetti;J Allergy Clin Immunol,2021

5. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial;DeAngelo;Leukemia,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mast Cell–Targeting Therapies in Mast Cell Activation Syndromes;Current Allergy and Asthma Reports;2024-01-13